investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

Molecular Analytical Robotics Assays

Investigator from Austrian Institute of Technology

0 Collaborator(s)

Funding source

European Commission (Belgium)
Diagnostic tests are essential to provide a targeted treatment of infectious diseases and to contain the further spread of multidrug resistant pathogens. Current methods are based either on cultivation or on PCR and have significant limitations concerning the clinical requirements to characterise pathogens including their resistance mechanisms within 3 hours. In MARA, we will develop and combine three radically novel technologies that will lead to substantial breakthroughs in science, medicine and industry and, as proof-of principle, use them to create a DNA-based molecular toolkit characterising pathogens. First, the detection of pathogen-associated antigens will be performed by Autonomous Detection Nucleic Acids (AUDENA) that are independent of any laboratory instruments and sophisticated processing. The realisation of the AUDENA concept will lead to an autonomous, stable, simple and very economic novel sensor class applicable for any water-soluble substances. The second revolutionary technology in MARA employs a novel approach in protein mimicry and creation of artificial enzymes, which represents a breakthrough in several disciplines, such as biotechnology, biomedical manufacturing and the energy sector. The third breakthrough in this project represents the development of a Molecular Robot (MORO) that can specifically identify target cells and destroy them. In MARA, the MORO will be used for the lysis of bacterial cells to release intracellular antibiotic resistance associated antigens, but the long-term vision anticipates an application as antibiotic replacement for infectious diseases and a therapeutic agent for cancer treatment, which would represent one of the most important breakthroughs in medicine in the recent years. To meet the highly ambitious objectives pointed out in this proposal, MARA is driven by a complementary, multidisciplinary team of leading experts, with a young, high-profile scientist in the lead.

Related projects